SOTERA HEALTH CO
SHCNASDAQTrading Snapshot
- Day Range
- $731.18 – $753.74
- 52-Week Range
- $12.95 – $19.85
- Volume
- $4.64B
- Avg Volume
- $4.47B
- Shares Outstanding
- 285.2M
- Next Earnings
- Oct 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.16B
- Last Q Revenue
- $321M
- P/E Ratio
- 46.0
- P/S Ratio
- 4.6x
- EPS (TTM)
- $0.41
- Dividend Yield
- —
Why Investors Own SHC
- ✓High-growth profile — revenue up +29.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SOTERA HEALTH CO
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Sotera Health Company (SHC) Reported Positive Results Amid Litigation Wins
US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index’s 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), […]
SHC Q2 Deep Dive: Broad-Based Growth, Leadership Transition, and Strategic Investments Shape Outlook
Healthcare services company Sotera Health (NASDAQ:SHC) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.2% year on year to $321.4 million. The company expects the full year’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.26 per share was 8.7% above analysts’ consensus estimates.
Sotera Health (SHC) Is Up 5.9% After Q2 Earnings Beat And Guidance Hike What’s Changed
Sotera Health Company’s Q2 2026 results, released on August 6, showed revenue rising to US$321.38 million and net income to US$53.64 million, with earnings per share from continuing operations increasing to US$0.19 from US$0.03 a year earlier. Management’s decision to raise full-year guidance after broad-based growth across Sterigenics, Nordion and Nelson Labs highlights improving profitability supported by pricing, volume mix and operational execution. We’ll now examine how Sotera Health’s...
Citigroup Maintains Buy on Sotera Health, Raises Price Target to $25
Citigroup analyst Brendan Digan maintains Sotera Health (NASDAQ:SHC) with a Buy and raises the price target from $23 to $25.
Barclays Maintains Overweight on Sotera Health, Raises Price Target to $22
Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and raises the price target from $19 to $22.
Piper Sandler Reiterates Overweight on Sotera Health, Raises Price Target to $25
Piper Sandler analyst Jason Bednar reiterates Sotera Health (NASDAQ:SHC) with a Overweight and raises the price target from $22 to $25.